Dr. Chintakuntlawar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13400 E Shea Blvd
Scottsdale, AZ 85259Phone+1 480-301-8000
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2012 - 2016
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2009 - 2012
Grant Medical CollegeClass of 2003
Certifications & Licensure
AZ State Medical License 2024 - 2025
MN State Medical License 2012 - 2024
Clinical Trials
- hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Start of enrollment: 2014 Dec 01
- Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Start of enrollment: 2017 May 31
Publications & Presentations
PubMed
- 119 citationsPhase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus–Associated Oropharynx Squamous Cell CarcinomaDaniel J. Ma, Katharine A. Price, Eric J. Moore, Samir H. Patel, Michael L. Hinni
Journal of Clinical Oncology. 2019-06-04 - 71 citationsChemokine CXCL1/KC and its Receptor CXCR2 Are Responsible for Neutrophil Chemotaxis in Adenoviral KeratitisAshish V. Chintakuntlawar, James Chodosh
Journal of Interferon & Cytokine Research. 2009-10-01 - 39 citationsAdenovirus type 37 keratitis in the C57BL/6J mouse.Ashish V. Chintakuntlawar, Roger A. Astley, James Chodosh
Investigative Ophthalmology & Visual Science. 2007-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
